FLGT Fulgent Genetics
- 20.700
- +0.350+1.72%
- 21.150
- +0.450+2.17%
Fulgent Genetics News
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Apr. 11, 2024-- Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business a
Reproductive Genetics Market Analysis Report 2024-2032, Featuring Bangkok Genomics Innovation, Centogene, Fulgent Genetics, Igenomix, Invitae, PerkinElmer and Thermo Fisher Scientific
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Express News | Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $25
Fulgent Genetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 7.67% Piper Sandler $28 → $25 Maintains Neutral 12/07/2023 50.73% UBS → $35 Initiates Coverage
Piper Sandler Sticks to Its Hold Rating for Fulgent Genetics (FLGT)
Revenues Not Telling The Story For Fulgent Genetics, Inc. (NASDAQ:FLGT)
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S") below 0.9x, Fulgent Genetics, Inc. (NASDAQ:FLGT) looks to be giving
An Intrinsic Calculation For Fulgent Genetics, Inc. (NASDAQ:FLGT) Suggests It's 32% Undervalued
Fulgent Genetics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating.
Express News | Fulgent Genetics Shares Are Trading Lower After the Company Reported Q4 Financial Results and Issued FY24 Guidance Below Estimates
Earnings Call Summary | Fulgent Genetics(FLGT.US) Q4 2023 Earnings Conference
The following is a summary of the Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript:Financial Performance:Fulgent Genetics reported Q4 revenue of $70 million, an increase compared to Q4 2022's
Fulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023
Fulgent Genetics Shares Business Insights in Investor Update
Express News | Fulgent Genetics Expects 2024 Core Revenue of Approximately $280M Versus Consensus Of $294.25M, With Adjusted EPS Loss Of Approximately $(1.05) Versus Consensus Of $(0.95)
Express News | Fulgent Genetics Q4 Adjusted EPS $0.28 May Not Be Comparable To $(0.29) Estimate, Sales $70.50M Beat $66.32M Estimate
Press Release: Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results -- Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million -- Full Year 2023 Core Reve
Fulgent Genetics 4Q Loss $128.1M >FLGT
Fulgent Genetics 4Q Loss $128.1M >FLGT
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. • Golden Ocean Group (NASDAQ:GOGL) is likely to report
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million Full Year 2023 Core Revenue grows 44% year-over-year to $262.1 million; Q4 2023 Core Revenue grows 21% year-ove
Analysis
Price Target
No Data
